IP Library › Granted Patent US 12,723,034
Granted Patent B2
US 12,723,034 · App. 19/381,972 · Granted Sep 1, 2026

Crystalline form of epigallocatechin-3-gallate

Inventors: George David McClure, Jr. (Huntsville, AL); Peter York (Bradford, GB); Steven Thomas Nicholson (Bradford, GB); Linda Sharon Daintree (Bradford, GB); Aishah Ashraf (Bradford, GB)
Assignee: PharmassětX Inc.
C07D311/62A61K31/353
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,723,034
App. No.
19/381,972
Granted
Sep 1, 2026
Kind
B2
Abstract

The disclosure relates to crystalline Form X of epigallocatetchin-3-gallate, compositions containing Form X, and methods of using Form X. The disclosure also relates to methods of making crystalline Form X of epigallocatetchin-3-gallate.

Claims (1)

1 . Crystalline Form X epigallocatechin-3-gallate characterized by an X-ray diffraction (XRPD) pattern having peaks at 6.4° , 9.7° , and 10.6° 2θ (±0.2° 2θ).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2026
From: MCCLURE, GEORGE DAVID, JR., DR.; NICHOLSON, STEVEN THOMAS; ASHRAF, AISHAH; DAINTREE, LINDA SHARON; YORK, PETER
To: PHARMASSÊTX INC.
Reel/Frame 073990/0553 →
Continuity (2)
Provisional Application 63718303 · Nov 8, 2024
Related Publication 20260167611A1 · Jun 18, 2026
References Cited (21)
US 8471044B2 · Zaworotko · 2013 [cited by examiner]
US 10813938B2 · Mehta · 2020 [cited by examiner]
US 20100173984A1 · Zaworotko et al. · 2010 [cited by applicant]
CN 109293617A · 2019 [cited by applicant]
WO 9501221A1 · 1995 [cited by applicant]
WO 9600610A1 · 1996 [cited by applicant]
WO 9836825A1 · 1998 [cited by applicant]
WO 9944733A1 · 1999 [cited by applicant]
WO 9959710A1 · 1999 [cited by applicant]
WO 0103821A1 · 2001 [cited by applicant]
WO 2008153938A2 · 2008 [cited by applicant]
WO 2015136551A2 · 2015 [cited by applicant]
WO 2025008082A1 · 2025 [cited by applicant]
Anish V. Dighe, et al., Crystal Growth & Design 2022 22 (5), 3119-3127. (Year: 2022). [cited by examiner]
Gaesser, Glenn A., et al. American Journal of Lifestyle Medicine 6.1 (2012): 4-13 (abstract). (Year: 2012). [cited by examiner]
Brittain, Harry G. “Polymorphism in pharmaceutical solids.” Drugs and the pharmaceutical sciences 95 (1999): 331-361. (Year: 1999). [cited by examiner]
CN109293617—google translation, printed May 14, 2026. (Year: 2026). [cited by examiner]
Adam J. Smith et al., Mol. Pharmaceutics 2013, 10, 2948-2961. (Year: 2013). [cited by examiner]
Li, et al., “The physical and chemical stability of amorphouse (-)-epi-gallocatechin gallate: Effects of water vapor sorption and storage temperature”, Food Research International 58, journal hompage: www.elsevier.com/l… [cited by applicant]
Smith, et al., “Crystal Engineering of Green Tea Epigallocatechin-3-gallate (EGCg) Cocrystals and Pharmacokinetic Modulation in Rats”, Molecular Pharmaceutics, pubs.acs.org/molecularpharmaceutics, pp. 2948-2961, (2013). [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority in related International Application No. PCT/US2025/054541 dated Mar. 11, 2026. [cited by applicant]